Abeona Therapeutics Inc.
ABEO
$5.33
-$0.07-1.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -12.00% | -9.35% | 9.48% | 16.42% | 5.09% |
| Gross Profit | 28.94% | 10.58% | -8.19% | -30.79% | -17.69% |
| SG&A Expenses | 117.85% | 92.58% | 59.26% | 46.92% | 57.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.37% | 37.63% | 32.08% | 28.92% | 24.20% |
| Operating Income | -39.30% | -36.97% | -31.37% | -37.86% | -33.22% |
| Income Before Tax | 211.84% | 216.38% | 238.32% | 42.36% | -17.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 211.69% | 215.93% | 208.83% | 42.36% | -17.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 211.69% | 215.93% | 208.83% | 42.36% | -17.62% |
| EBIT | -39.30% | -36.97% | -31.37% | -37.86% | -33.22% |
| EBITDA | -39.69% | -37.75% | -32.30% | -39.66% | -35.49% |
| EPS Basic | 176.19% | 168.76% | 148.24% | 72.63% | 30.73% |
| Normalized Basic EPS | 14.88% | 40.24% | 23.73% | 73.10% | 32.23% |
| EPS Diluted | 144.35% | 143.52% | 125.28% | 58.61% | 13.37% |
| Normalized Diluted EPS | 22.93% | 46.24% | 30.48% | 71.86% | 30.70% |
| Average Basic Shares Outstanding | 29.05% | 45.45% | 68.96% | 94.68% | 92.11% |
| Average Diluted Shares Outstanding | 28.85% | 44.00% | 65.21% | 106.38% | 105.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |